Roivant Sciences' Eric Venker plans $7.62M share sale

The notice also lists six prior sales from August 20 through November 3, 2026.

Available on EDGAR 11/10/2026 - 04:36 PM EST Accepted by SEC EDGAR 11/10/2026 - 04:36 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Roivant Sciences Ltd. reports that its officer Eric Venker plans to sell 187,943 common shares, with an aggregate market value of $7,617,816.56. The approximate sale date is November 10, 2026, and Rockefeller Financial LLC is named as broker.

The proposed sale is pursuant to a Rule 10b5-1 trading plan adopted June 30, 2026. The notice also lists earlier sales: 13,909 shares on August 20, 2026, and 200,000 shares on each of August 28, September 30, October 20, October 28, and November 3, 2026.

Key Figures

Proposed shares to be sold: 187,943 shares Aggregate market value: $7,617,816.56 Common shares outstanding: 724,561,460 shares +2 more

5 metrics

Proposed shares to be sold 187,943 shares Approximate sale date: November 10, 2026

Aggregate market value $7,617,816.56 Proposed sale of common shares

Common shares outstanding 724,561,460 shares Reported in the securities information

Shares sold November 3, 2026 200,000 shares Reported sale during the prior three months

Gross proceeds from November 3, 2026 sale $7,262,568.00 Reported sale of common shares

Key Terms

Rule 10b5-1 trading plan, RSU Grant, Options Exercise

3 terms

Rule 10b5-1 trading plan regulatory

"sold pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

RSU Grant financial

"RSU Grant"

Options Exercise financial

"Options Exercise"

Exercising an option is the act of using a contract that gives you the right to buy or sell a specific stock at a set price. For investors, the decision to exercise matters because it turns a paper right into an actual trade — it can create immediate profit or loss, change how many shares are outstanding (which can dilute ownership), affect cash the investor must pay or receive, and trigger tax consequences, much like deciding to redeem a coupon for a fixed-price purchase.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ROIV shares does Eric Venker plan to sell?

Eric Venker reported a proposed sale of 187,943 common shares, with an aggregate market value of $7,617,816.56. The approximate sale date is November 10, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001801917
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Roivant Sciences Ltd.
SEC File Number	001-40782
Address of Issuer	7TH FLOOR, 50 BROADWAY LONDON UNITED KINGDOM SW1H 0DB
Phone	441-295-5950
Name of Person for Whose Account the Securities are To Be Sold	Venker Eric
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Rockefeller Financial LLC 45 Rockefeller Plaza Floor 5 New York NY 10111	187943	7617816.56	724561460	11/10/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Shares	03/20/2025	Options Exercise - Grant Date 04/20/2022	Roivant Sciences Ltd.			51725	03/20/2025	n/a
Common Shares	02/13/2025	Options Exercise - Grant Date 04/20/2022	Roivant Sciences Ltd.			17351	02/13/2025	n/a
Common Shares	03/20/2023	RSU Grant 018305 - Grant date 05/20/2020	Roivant Sciences Ltd			4657	03/20/2023	n/a
Common Shares	02/20/2023	RSU Grant 018305 - Grant date 05/20/2020	Roivant Sciences Ltd			5367	02/20/2023	n/a
Common Shares	01/20/2023	RSU Grant 018305 - Grant date 05/20/2020	Roivant Sciences Ltd			4770	01/20/2023	n/a
Common Shares	11/20/2024	RSU Grant 018861 - Grant date 05/20/2021	Roivant Sciences Ltd			17694	11/20/2024	n/a
Common Shares	10/20/2024	RSU Grant 018861 - Grant date 05/20/2021	Roivant Sciences Ltd			17694	10/20/2024	n/a
Common Shares	03/20/2024	RSU Grant 018861 - Grant date 05/20/2021	Roivant Sciences Ltd			8847	03/20/2024	n/a
Common	06/20/2023	RSU Grant 018861 - Grant date 05/20/2021	Roivant Sciences Ltd			8929	06/20/2023	n/a
Common Shares	05/20/2023	RSU Grant 018861 - Grant date 05/20/2021	Roivant Sciences Ltd			9074	05/20/2023	n/a
Common Shares	04/20/2023	RSU Grant 018861 - Grant date 05/20/2021	Roivant Sciences Ltd			9021	04/20/2023	n/a
Common Shares	03/20/2023	RSU Grant 018861 - Grant date 05/20/2021	Roivant Sciences Ltd			10085	03/20/2023	n/a
Common shares	02/20/2023	RSU Grant 018861 - Grant date 05/20/2021	Roivant Sciences Ltd			11619	02/20/2023	n/a
Common Shares	01/20/2023	RSU Grant 018861 - Grant date 05/20/2021	Roivant Sciences Ltd			11110	01/20/2023	n/a

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway, London X0 SW1H0DB	Common Shares	08/20/2026	13909	512407.56
Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H0DB	Common Shares	08/28/2026	200000	7147087.91
Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H0DB	Common Shares	09/30/2026	200000	7323556.00
Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H0DB	Common Shares	10/20/2026	200000	7023153.39
Eric Venker c/o Roivant Sciences Ltd 7th Floor, 50 Broadway London X0 SW1H0DB	Common Shares	10/28/2026	200000	7317764.00
Eric Venker c/o Roivant Sciences Ltd 7th Floor, 50 Broadway, London X0 SW1H0DB	Common Shares	11/03/2026	200000	7262568.00

144: Remarks and Signature

Remarks	The shares reported on this Form 144 will be sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 06/30/2026.
Date of Notice	11/10/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/30/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Carmen Zamores as a duly authorized representative of National Financial Services LLC, as attorney-in-fact for Venker Eric
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)